title: Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis.
abstract: OBJECTIVE
  To assess the effect on spermatogenesis of adding recombinant follicle-stimulating hormone (FSH) to human chorionic gonadotropin (hCG) treatment protocols for adolescent/young adult males with hypogonadotropic hypogonadism (HH).
  
  
  METHODS
  Observational descriptive study.
  
  
  METHODS
  Outpatient clinics.
  
  
  METHODS
  Nineteen males with hypogonadotropic hypogonadism, aged 14.5 to 31.0 years.
  
  
  METHODS
  Treatment with either hCG treatment alone (n = 9; group 1) or in combination with recombinant FSH (n = 10; group 2), over 6 to 9 months.
  
  
  METHODS
  Combined testicular volume (CTV) and testosterone, inhibin B, semen/urine analysis at 6 to 9 months.
  
  
  RESULTS
  There were no differences between the two groups in baseline variables or changes in CTV with treatment. Despite this, evidence of spermatogenesis was present in all group 2 patients by 9 months (range 0.2 to 15 × 10(6)/mL) compared with three of nine patients in group 1 (range 0 to <1 × 10(6)/mL). Whole group and subgroup analyses did not demonstrate any statistically significant correlations between age at onset of treatment and either CTV or sperm count.
  
  
  CONCLUSIONS
  The addition of recombinant FSH to hCG treatment protocols in adolescent/young adult HH males results in normal testicular growth and may hasten induction of spermatogenesis.
authors: Murdoch Childrens Research Institute, Royal Children's Hospital and University of Melbourne, Parkville, Victoria, Australia. margaret.zacharin@rch.org.au
authors: Margaret
authors: M
authors: Zacharin
authors: Matthew A
authors: MA
authors: Sabin
authors: Veena V
authors: VV
authors: Nair
authors: Preeti
authors: P
authors: Dabadghao
authors: Preeti
authors: P
authors: Dagabdhao
mesh_terms: D000293:Adolescent; D000328:Adult; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D043373:Follicle Stimulating Hormone, Human / Q000627:therapeutic use*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010045:Outpatients; D011627:Puberty / Q000187:drug effects / Q000502:physiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D012102:Reproductive Control Agents / Q000627:therapeutic use; D013091:Spermatogenesis / Q000187:drug effects* / Q000502:physiology; D013737:Testis / Q000187:drug effects* / Q000254:growth & development* / Q000473:pathology; D055815:Young Adult
chemical_list: D006063:Chorionic Gonadotropin; D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins; D012102:Reproductive Control Agents